A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Phase 2
Completed
NCT05024994
| Condition | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
|---|
| Status | Completed |
|---|
| Enrollment | 12 participants |
|---|
| Interventions | E7820 |
|---|
| Start date | Aug 13, 2021 |
|---|
| Completion date | Jun 19, 2025 |
|---|
| Results posted | Jun 17, 2026 |
|---|
Summary
The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).
Median Overall Survival
1 year · months
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.